| 2. |
- Hemmilä, Venla, 1987-, et al.
(author)
-
Influencing factors, repeatability and correlation of chamber methods in measuring formaldehyde emissions from fiber- and particleboards
- 2019
-
In: International Journal of Adhesion and Adhesives. - : Elsevier. - 0143-7496 .- 1879-0127. ; 95, s. 1-9
-
Journal article (peer-reviewed)abstract
- Recently, there has been focus on lowering emission levels of wood-based boards. However, the accuracy and correlationbetween EN 717-1 and ASTM D 6007 chamber methods at emission levels below 0.05 ppm are not wellinvestigated, and information about their correlation to the EN 16516 method is limited. In this paper, the lowemission level of interest was determined by measuring emissions from particles, fibers and pressed boards withoutglue. The effect of analytical methods and edge-sealing on chamber emissions was determined, and accuracies andcorrelations of the EN 717-1 and ASTM D 6007 chambers were defined at low emission levels (< 0.05 ppm). Inaddition, some emission values were compared to those obtained with EN 16516. The EN 717-1 and ASTM D 6007methods had high accuracy. The acetyl acetone and 2.4-dinitrophenylhydrazine analytical methods showed lowstandard deviations (< 5%), except at emission levels below 0.02 ppm. This could be counteracted by using a directreagent absorber solution. Opening 5% of the edge of boards affected emissions and was dependent on board type.ASTM D 6007 and EN 717-1 methods were highly correlated for both particleboards (r2=0.9167) and fiberboards(r2=0.9443) at emission levels below 0.05 ppm. EN 16516 emissions were 2.6 times greater than those of EN 717-1 at emission range<0.05 ppm, exceeding the conversion factor of two given in the German legislation. The EN 717-1 to EN 16516 correlation needs to be further evaluated for different board types and emission ranges
|
|
| 3. |
- Wendt, Ralph, et al.
(author)
-
A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients.
- 2021
-
In: Lancet EClinicalMedicine. - : Elsevier BV. - 2589-5370. ; 36
-
Journal article (peer-reviewed)abstract
- COVID-19 prediction models based on clinical characteristics, routine biochemistry and imaging, have been developed, but little is known on proteomic markers reflecting the molecular pathophysiology of disease progression.he multicentre (six European study sites) Prospective Validation of a Proteomic Urine Test for Early and Accurate Prognosis of Critical Course Complications in Patients with SARS-CoV-2 Infection Study (Crit-COV-U) is recruiting consecutive patients (≥ 18 years) with PCR-confirmed SARS-CoV-2 infection. A urinary proteomic biomarker (COV50) developed by capillary-electrophoresis-mass spectrometry (CE-MS) technology, comprising 50 sequenced peptides and identifying the parental proteins, was evaluated in 228 patients (derivation cohort) with replication in 99 patients (validation cohort). Death and progression along the World Health Organization (WHO) Clinical Progression Scale were assessed up to 21 days after the initial PCR test. Statistical methods included logistic regression, receiver operating curve (ROC) analysis and comparison of the area under the curve (AUC).in the derivation cohort, 23 patients died, and 48 developed worse WHO scores. The odds ratios (OR) for death per 1 standard deviation (SD) increment in COV50 were 3·52 (95% CI, 2·02-6·13, p<0·0001) unadjusted and 2·73 (1·25-5·95, p = 0·012) adjusted for sex, age, baseline WHO score, body mass index (BMI) and comorbidities. For WHO scale progression, the corresponding OR were 2·63 (1·80-3·85, p<0·0001) and 3·38 (1·85-6·17, p<0·0001), respectively. The area under the curve (AUC) for COV50 as a continuously distributed variable was 0·80 (0·72-0·88) for mortality and 0·74 (0·66-0·81) for worsening WHO score. The optimised COV50 thresholds for mortality and worsening WHO score were 0·47 and 0·04 with sensitivity/specificity of 87·0 (74·6%) and 77·1 (63·9%), respectively. On top of covariates, COV50 improved the AUC, albeit borderline for death, from 0·78 to 0·82 (p = 0·11) and 0·84 (p = 0·052) for mortality and from 0·68 to 0·78 (p = 0·0097) and 0·75 (p = 0·021) for worsening WHO score. The validation cohort findings were confirmatory.this first CRIT-COV-U report proves the concept that urinary proteomic profiling generates biomarkers indicating adverse COVID-19 outcomes, even at an early disease stage, including WHO stages 1-3. These findings need to be consolidated in an upcoming final dataset.
|
|
